Hamid Ahmadieh, MD (Tehran, Iran), Homa Tabatabaei, MD (Tehran, Iran), Mostafa Feghi, MD (Ahvaz, Iran), Ardeshir Papi, MD (Tehran, Iran), Alireza Ramezani, MD (Tehran, Iran), Touka Banaee, MD (Mashhad, Iran)


To evaluate the effect of triamcinolone acetonide (TA) injection in silicone-filled eyes on the outcomes of surgery for established proliferative vitreoretinopathy (PVR).


A prospective, controlled, randomized clinical trial was conducted. All patients underwent pars plana vitrectomy, membrane peeling and silicone oil exchange with or without relaxing retinotomy/retinectomy. In the treatment group, 4mg TA was injected into the siliconefilled vitreous cavity. The primary outcome measure was retinal reattachment rate after silicone oil removal at 6 months. Secondary outcome measures included visual acuity, PVR recurrence rate, intraocular pressure and early silicone oil emulsification.


Seventy five eyes with retinal detachment complicated by PVR grade C (posterior and/ or anterior) were included in this study. Of these, 38 eyes were in the treatment group and 37 eyes were in the control group. Single-operation  retinal reattachment was gained in 32 (84.2%) and 29 (78.4%) eyes in the treatment and control groups respectively after 6 months. There was no statistically significant difference between the two groups (P? 0.5). There was also no meaningful difference between the two groups regarding the secondary outcome measures.


The outcome of vitreoretinal surgery for established PVR is not affected by triamcinolone acetonide in silicone-filled eyes.